TriSalus Life Sciences, Inc.
6272 W. 91st Ave.
Westminster, Colorado 80031
November 6, 2024
Securities and Exchange Commission
Division of Corporation Finance
Office of Industrial Applications and Services
100 F. Street N.E.
Washington, D.C. 20549-3010
Attention: Robert Augustin
| Re: | TriSalus Life Sciences, Inc. |
| Registration Statement on Form S-3 | |
| File No. 333-282882 | |
Ladies and Gentlemen:
TriSalus Life Sciences, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on Friday, November 8, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Dylan Kornbluth of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Dylan Kornbluth of Cooley LLP, counsel to the Registrant, at (858) 550-6173.
[Signature Page Follows]
| Very truly yours, | ||
| TRISALUS LIFE SCIENCES, INC. | ||
| By: | /s/ Mary Szela | |
| Name: Mary Szela | ||
| Title: Chief Executive Officer | ||
| cc: | Carlos Ramirez, Cooley LLP |
| Matthew T. Browne, Cooley LLP | ||
| Dylan Kornbluth, Cooley LLP | ||
[Company Signature Page to Acceleration Request]